| Srinivasa Kakumani, MD | |
|
1025 S 6th St, Springfield, IL 62703 | |
| (217) 528-7541 | |
| Not Available |
| Full Name | Srinivasa Kakumani |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 29 Years |
| Location | 1025 S 6th St, Springfield, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508988486 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 036123871 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Medical Center | Springfield, IL | Hospital |
| Abraham Lincoln Memorial Hospital | Lincoln, IL | Hospital |
| St Johns Hospital | Springfield, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Springfield Clinic Llp | 0547166076 | 669 |
News Archive
The gene therapy-based research project to tackle Friedreich's ataxia launched in November in labs at the Institute for Research in Biomedicine, in Barcelona, and the "Centro de Biolog-a Molecular Severo Ochoa", in Madrid, has received 100,000 US$ per year for two years from the Friedreich's Ataxia Research Alliance.
The brain undergoes dramatic change during the first years of life. Its circuits readily rewire as an infant and then child encounters new sights and sounds, taking in the world and learning to understand it. As the child matures and key developmental periods pass, the brain becomes less malleable-but certain experiences create opportunities for parts of the adult brain to rewire and learn again.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Researchers at the University of Montreal Hospital Research Centre have identified a promising solution to improving treatments offered to patients with cystic fibrosis.
Stem cell researchers at UConn Health have reversed Prader-Willi syndrome in brain cells growing in the lab, findings they recently published in the Human Molecular Genetics.
› Verified 1 days ago
| Entity Name | Springfield Clinic Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780638478 PECOS PAC ID: 0547166076 Enrollment ID: O20040331000826 |
News Archive
The gene therapy-based research project to tackle Friedreich's ataxia launched in November in labs at the Institute for Research in Biomedicine, in Barcelona, and the "Centro de Biolog-a Molecular Severo Ochoa", in Madrid, has received 100,000 US$ per year for two years from the Friedreich's Ataxia Research Alliance.
The brain undergoes dramatic change during the first years of life. Its circuits readily rewire as an infant and then child encounters new sights and sounds, taking in the world and learning to understand it. As the child matures and key developmental periods pass, the brain becomes less malleable-but certain experiences create opportunities for parts of the adult brain to rewire and learn again.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Researchers at the University of Montreal Hospital Research Centre have identified a promising solution to improving treatments offered to patients with cystic fibrosis.
Stem cell researchers at UConn Health have reversed Prader-Willi syndrome in brain cells growing in the lab, findings they recently published in the Human Molecular Genetics.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Srinivasa Kakumani, MD 1025 S 6th St, Springfield, IL 62703-2403 Ph: (217) 528-7541 | Srinivasa Kakumani, MD 1025 S 6th St, Springfield, IL 62703 Ph: (217) 528-7541 |
News Archive
The gene therapy-based research project to tackle Friedreich's ataxia launched in November in labs at the Institute for Research in Biomedicine, in Barcelona, and the "Centro de Biolog-a Molecular Severo Ochoa", in Madrid, has received 100,000 US$ per year for two years from the Friedreich's Ataxia Research Alliance.
The brain undergoes dramatic change during the first years of life. Its circuits readily rewire as an infant and then child encounters new sights and sounds, taking in the world and learning to understand it. As the child matures and key developmental periods pass, the brain becomes less malleable-but certain experiences create opportunities for parts of the adult brain to rewire and learn again.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
Researchers at the University of Montreal Hospital Research Centre have identified a promising solution to improving treatments offered to patients with cystic fibrosis.
Stem cell researchers at UConn Health have reversed Prader-Willi syndrome in brain cells growing in the lab, findings they recently published in the Human Molecular Genetics.
› Verified 1 days ago
Zachariah Gurnsey, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 751 N Rutledge St, Ste 1100, Springfield, IL 62702 Phone: 217-545-0182 Fax: 217-545-8156 | |
Mr. Eddie Lynn Paulk, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2090 Vadalabene Drive, Springfield, IL 62062 Phone: 618-288-5403 Fax: 618-288-6857 | |
Winston J Townsend, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1836 S Macarthur Blvd, Springfield, IL 62704 Phone: 217-789-1403 Fax: 217-789-1825 | |
William R Yu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2901 Old Jacksonville Rd, Springfield, IL 62704 Phone: 217-698-9722 Fax: 217-698-8012 | |
Dr. Susan M. O'neal, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 701 N 1st St, Springfield, IL 62781 Phone: 217-528-7541 | |
Dr. Mukul Bhattarai, MD. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 747 N Rutledge St Fl 4, Springfield, IL 62702 Phone: 217-545-8000 Fax: 217-545-7877 | |
Nathalie Emma-marie Foray, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 751 N Rutledge St Ste 1700, Springfield, IL 62702 Phone: 217-545-8000 Fax: 217-545-1229 |